prof. dr. M.J. (Maarten) Postma

Professor Global Health Economics UMCG & RUG

prof. dr. M.J. (Maarten) Postma
Telephone:
E-mail:
m.j.postma rug.nl

Research

  1. 2002
  2. Postma, M., & Brouwers, J. (2002). Farmaco-economische analyse van vaccins. Conceptuur, 31, 18-20.
  3. Postma, M., Dronkers, F., Kuipers, GE., & Beck, EJ. (2002). Farmaco-economische aspecten van HIV/Aids. Capita Selecta HIV/Aids, 1-8.
  4. Postma, M., & Brouwers, J. (2002). Groeiend belang farmaco-economie. Conceptuur, 30, 14-15.
  5. Postma, MJ., Jansema, P., van Genugten, MLL., Heijnen, MLA., Jager, JC., & de Jong-van den Berg, LTW. (2002). Pharmacoeconomics of influenza vaccination for healthy working adults - Reviewing the available evidence. DRUGS, 62(7), 1013-1024.
  6. 2001
  7. Postma, M., Welte, R., van den Hoek, J. A., van Doornum, G. J., Jager, H. C., & Coutinho, R. A. (2001). Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis. Value in Health, 4(3), 266-275.
  8. Postma, MJ., Los, APM., Ruitenberg, EJ., & Sibinga, CTS. (2001). Cost-effectiveness of HIVNAT screening for Dutch donors. In CTS. Sibinga, & JD. Cash (Eds.), TRANSFUSION MEDICINE: QUO VADIS? WHAT HAS BEEN ACHIEVED, WHAT IS TO BE EXPECTED (pp. 45-51). (DEVELOPMENTS IN HEMATOLOGY AND IMMUNOLOGY; Vol. 36). DORDRECHT: Springer.
  9. Postma, M., & Kuipers, EW. (2001). De kosten van HIV/Aids. Pharmaceutisch Weekblad, 136, 937-946.
  10. Postma, M., Heijnen, M-LA., & Jager, JC. (2001). Kosten-effectiviteitsanalyse van pneumokokkenvaccinatie voor Nederlandse 65+'ers. In R. van Furth (Ed.), Pneumokokkeninfecties in de 21e eeuw (pp. 71-80). (Boerhaave Cursussen).
  11. Postma, M., Rutten, WJMJ., & de Vries, C. (2001). Langs de valkuilen (8) Farmaco-economisch onderzoek. Pharmaceutisch Weekblad, 136(41), 1542-1545.
  12. Postma, M., Tolley, K., & Jager, JC. (2001). Modelling the health-care costs of drug-use-related disease: Part V: Economic Models, Chapter 12. In Modelling drug use: methods to quantify and understand hidden processes (pp. 205-220). (EMCDDA Scientific Monograph Series).
  13. de Walle, H., de Smit, DJ., Pal-de Bruin, K., Postma, M., & de Jong-van den Berg, L. (2001). Opinie: Foliumzuur en verrijking: terug bij af. Pharmaceutisch Weekblad, 136(9), 282-325.
  14. Jager, JC., Postma, M., & Achterberg , PW. (2001). Part IV: Modelling the health consequences of drug use, Chapter 11: Developing multinational scenario analysis of health impacts of drug use. In Modelling drug use: methods to quantify and understand hidden processes (pp. 183-201). (EMCDDA Scientific Monograph Series ).
  15. Godfrey, C., Parrot, S., Sutton, M., Waby, V., Young, P., Comiskey , C., ... Wiessing, L. (2001). Part 1: What is modelling and how can it be used? In Modelling drug use: methods to quantify and understand hidden processes (Vol. chapter 2, pp. 33-52). (EMCDDA Scientific Monograph Series ).
  16. Postma, M., Smit Sibinga, C. T., & Ruitenberg, EJ. (2001). Pharmaco-economics of transfusion safety. In CT. Smit Sibinga, & JD. Cash (Eds.), Quo Vadis (pp. 45-51). Londen: Kluwer.
  17. 2000
  18. Postma, M. J., Bakker, A., Welte, R., Van Bergen, J. E. A. M., Van den Hoek, J. A. R., De Jong-Van den Berg, L. T. W., & Jager, J. C. (2000). Screening op Asymptomatische Chlamydia. Nederlands Tijdschrift voor Geneeskunde, 144(49), 2350-2354.
  19. Postma, MJ., Beck, EJ., Hankins, CA., Mandalia, S., Jager, JC., de Jong-van den Berg, LTW., & Sherr, L. (2000). Cost effectiveness of expanded antenatal HIV testing in London. Aids, 14(15), 2383-2389.
  20. Postma, MJ., Baltussen, RMPM., Heijnen, MLA., de Jong-van den Berg, LTW., & Jager, JC. (2000). Pharmacoeconomics of influenza vaccination in the elderly - Reviewing the available evidence. Drugs & Aging, 17(3), 217-227.
  21. Postma, M., Welte, R., van den Hoek, A., van Doornum, G., Mulder-Folkerts, D., Couthino, RA., & Jager, JC. (2000). Cost-effectiveness of screening asymptomatic women for Chlamydia trachomatis: The importance of reinfection and partner referral. Value in Health, 4(3), 266-275.
  22. Struijs, JN., Wit, GAD., Kretzschmar, M. E. E., Smits , LJM., Postma, M., van der Laar, MWJ., & Jager, JC. (2000). Kosten en effecten van algemene vaccinatie tegen hepatitis. Infectieziekten Bulletin, 11(7), 109-144.
  23. 1999
  24. Postma, M. J., Welte, R., Van Den Hoek, J. A. R., Jager, J. C., Van Doornum, G. J. J., & Coutinho, R. A. (1999). Opportunistische Screening op Chlamydia. Nederlands Tijdschrift voor Geneeskunde, 143(47), 2383-2385.
  25. Rutten-van Mölken, M. P., Postma, M., Joore, M. A., Van Genugten, M. L., Leidl, R., & Jager, J. C. (1999). Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respiratory Medicine, 93(11), 779 - 787.
  26. Postma, M., Beck, E. J., Mandalia, S., Sherr, L., Walters, M. D., Houweling, H., & Jager, J. C. (1999). Universal HIV screening of pregnant women in England: cost effectiveness analysis. BMJ Magazine, 318(7199), 1656-1660. https://doi.org/10.1136/bmj.318.7199.1656
  27. Postma, M. J., Bos, J. M., Van Gennep, M., Jager, J. C., Baltussen, R., & Sprenger, M. J. W. (1999). Economic evaluation of influenza vaccination: Assessment for The Netherlands. Pharmacoeconomics, 16(SUPPL. 1), 33-40. https://doi.org/10.2165/00019053-199916001-00005

ID: 193217